New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:46 EDTIPXL, AVNRAvanir likely win patent case against Impax, says Jefferies
After reviewing court transcripts, Jefferies believes Avanir (AVNR) is likely to win its Nuedexta patent trial against Impax (IPXL). The firm says that while the stock is may rally on the patent win, it sees limited upside and keeps a Hold rating on Avanir. Jefferies notes that its $4 price target already assumes full credit for the Nuedexta patent.
News For AVNR;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
16:57 EDTAVNRAvanir receives CRL from FDA on AVP-825
Subscribe for More Information
07:48 EDTAVNRFDA PDUFA Date for Avanir's AVP-825 is November 26, 2014
Subscribe for More Information
November 24, 2014
10:32 EDTAVNRDoctors viewing Avanir AVP-923 data favorably, says Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use